Clevexel Pharma SAS – Product Pipeline Review – 2015
Global Markets Direct’s, ‘Clevexel Pharma SAS – Product Pipeline Review – 2015’, provides an overview of the Clevexel Pharma SAS’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Clevexel Pharma SAS’s, complete with comparative analysis at various stages, therapeutics….
Total Pages: 31
Global Markets Direct’s, ‘Clevexel Pharma SAS - Product Pipeline Review - 2015’, provides an overview of the Clevexel Pharma SAS’s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Clevexel Pharma SAS’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides brief overview of Clevexel Pharma SAS including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Clevexel Pharma SAS’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Clevexel Pharma SAS’s pipeline products
Reasons to buy
- Evaluate Clevexel Pharma SAS’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Clevexel Pharma SAS in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Clevexel Pharma SAS’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Clevexel Pharma SAS and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Clevexel Pharma SAS
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Clevexel Pharma SAS and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Clevexel Pharma SAS Snapshot 5
Clevexel Pharma SAS Overview 5
Key Information 5
Key Facts 5
Clevexel Pharma SAS - Research and Development Overview 6
Key Therapeutic Areas 6
Clevexel Pharma SAS - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Clevexel Pharma SAS - Pipeline Products Glance 12
Clevexel Pharma SAS - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Clevexel Pharma SAS - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Clevexel Pharma SAS - Unknown Stage Pipeline Products 15
Unknown Products/Combination Treatment Modalities 15
Clevexel Pharma SAS - Drug Profiles 16
CVXL-0107 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
CVXL-0056 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
CVXL-0069 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CVXL-0103 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Small Molecule 1 for Malaria 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Small Molecule 2 for Malaria 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
CVXL-0095 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Clevexel Pharma SAS - Pipeline Analysis 23
Clevexel Pharma SAS - Pipeline Products by Target 23
Clevexel Pharma SAS - Pipeline Products by Route of Administration 24
Clevexel Pharma SAS - Pipeline Products by Molecule Type 25
Clevexel Pharma SAS - Pipeline Products by Mechanism of Action 26
Clevexel Pharma SAS - Recent Pipeline Updates 27
Clevexel Pharma SAS - Dormant Projects 28
Clevexel Pharma SAS - Locations And Subsidiaries 29
Head Office 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 30
Disclaimer 31
List of Tables
Clevexel Pharma SAS, Key Information 5
Clevexel Pharma SAS, Key Facts 5
Clevexel Pharma SAS - Pipeline by Indication, 2015 7
Clevexel Pharma SAS - Pipeline by Stage of Development, 2015 8
Clevexel Pharma SAS - Monotherapy Products in Pipeline, 2015 9
Clevexel Pharma SAS - Partnered Products in Pipeline, 2015 10
Clevexel Pharma SAS - Partnered Products/ Combination Treatment Modalities, 2015 11
Clevexel Pharma SAS - Phase II, 2015 12
Clevexel Pharma SAS - Preclinical, 2015 13
Clevexel Pharma SAS - Discovery, 2015 14
Clevexel Pharma SAS - Unknown, 2015 15
Clevexel Pharma SAS - Pipeline by Target, 2015 23
Clevexel Pharma SAS - Pipeline by Route of Administration, 2015 24
Clevexel Pharma SAS - Pipeline by Molecule Type, 2015 25
Clevexel Pharma SAS - Pipeline Products by Mechanism of Action, 2015 26
Clevexel Pharma SAS - Recent Pipeline Updates, 2015 27
Clevexel Pharma SAS - Dormant Developmental Projects,2015 28
List of Figures
Clevexel Pharma SAS - Pipeline by Top 10 Indication, 2015 7
Clevexel Pharma SAS - Pipeline by Stage of Development, 2015 8
Clevexel Pharma SAS - Monotherapy Products in Pipeline, 2015 9
Clevexel Pharma SAS - Pipeline by Top 10 Target, 2015 23
Clevexel Pharma SAS - Pipeline by Top 10 Route of Administration, 2015 24
Clevexel Pharma SAS - Pipeline by Top 10 Molecule Type, 2015 25
Clevexel Pharma SAS - Pipeline Products by Top 10 Mechanism of Action, 2015 26